Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/17017Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | O'Brien, Bernie J. | en_US |
| dc.contributor.author | Anderson, David. | en_US |
| dc.contributor.author | Goeree, Ron. | en_US |
| dc.contributor.author | Centre for Health Economics and Policy Analysis | en_US |
| dc.date.accessioned | 2015-04-14T14:41:58Z | - |
| dc.date.available | 2015-04-14T14:41:58Z | - |
| dc.date.issued | 1993 | en_US |
| dc.identifier.uri | http://hdl.handle.net/11375/17017 | - |
| dc.description | Bernie J. O'Brien, David Anderson, Ron Goeree. -- | en_US |
| dc.description | Bibliography: leaves 19-22. | en_US |
| dc.format.extent | 23 leaves. | en_US |
| dc.publisher | McMaster University | en_US |
| dc.relation.ispartofseries | CHEPA working paper series no. 93-6 | en_US |
| dc.subject | Cost-Benefit Analysis | en_US |
| dc.subject | Heparin, Low-Molecular Weight | en_US |
| dc.subject | therapeutic use | en_US |
| dc.subject | Heparin, Low-Molecular Weight | en_US |
| dc.subject | economics | en_US |
| dc.subject | Hip Prosthesis | en_US |
| dc.subject | complications | en_US |
| dc.subject | Thrombophlebitis | en_US |
| dc.subject | prevention & control | en_US |
| dc.subject | Warfarin | en_US |
| dc.subject | therapeutic use | en_US |
| dc.subject | Warfarin | en_US |
| dc.subject | economics | en_US |
| dc.subject | Economics, Medical | en_US |
| dc.title | Cost-effectiveness of enoxaparin versus warfarin for prevention of deep vein thrombosis following total hip replacement | en_US |
| dc.title.alternative | Enoxaparin versus warfarin for prevention of deep vein thrombosis following total hip replacement | en_US |
| dc.type | text | en_US |
| Appears in Collections: | CHEPA Working Paper Series | |
Files in This Item:
There are no files associated with this item.
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.
